BELFAST, Noord-Ierland–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd, een particulier gespecialiseerd bedrijf voor therapeutische en medicijnafgifte dat geneesmiddelen met aanhoudende afgifte voor belangrijke gezichtsbedreigende oogziekten, heeft vandaag …
Author: Business Wire
Re-Vana Therapeutics lève 3,25 millions de dollars dans un financement de pré-série A
BELFAST, Irlande du Nord–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd, une société privée de thérapies spécialisées et d’administration médicamenteuse développant des agents thérapeutiques à libération prolongée pour lutter contre des pathologies oculair…
Riassunto: Re-Vana Therapeutics raccoglie 3,25 milioni di dollari nell'ambito di un finanziamento pre-serie A
BELFAST, Irlanda del Nord–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd, una società a capitale privato che opera nel settore delle terapie speciali e della somministrazione di farmaci a rilascio prolungato per patologie oculari con significative ripercus…
Glaukos Announces Participation in the William Blair 40th Annual Growth Stock Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Re-Vana Therapeutics wirbt 3,25 Millionen USD in einer Serie A Vorfinanzierungsrunde ein
BELFAST, Nordirland–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd ist ein in Privatbesitz befindliches Unternehmen für Spezialtherapeutika und Medikamentenverabreichung, das Therapeutika mit verzögerter Wirkstofffreisetzung für schwere, sehkraftbedrohende…
Change Healthcare Launches Connected Consumer Health™ Suite
NASHVILLE, Tenn.–(BUSINESS WIRE)– #ChangeHealthcare–Change Healthcare unveils the Connected Consumer Health™ suite, a consumer and financial engagement platform collaboration with Adobe and Microsoft.
Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing
BELFAST, Northern Ireland–(BUSINESS WIRE)– #drugdelivery–Re-Vana Therapeutics Ltd, a specialty ocular therapeutic and drug delivery company, has closed $3.25 million in pre-series A financing.
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK–(BUSINESS WIRE)–IVERIC bio reported that it granted to two newly hired, non-executive employees non-statutory stock options to purchase 34,000 shares of common stock.
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves’ Ophthalmopathy
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China–(BUSINESS WIRE)–Harbour BioMed receives IND approval in China to begin seamless Phase 2/3 clinical trial of HBM9161 in Graves’ ophthalmopathy.
VisionQuest Biomedical Inc. and The University of New Mexico Combine Artificial Intelligence and Infrared Imaging to Diagnose Early Signs of Diabetic Foot
ALBUQUERQUE, N.M.–(BUSINESS WIRE)– #ai–VisionQuest Biomedical Inc. and the University of New Mexico School of Medicine have been awarded a three-year $3 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),…
Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditi…
Dr. Gil Kliman and Tom Frinzi Appointed to STAAR Surgical Board of Directors
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointment of Gilbert H. Kliman, M.D., Ma…
EyeSouth Partners Enters Sixth State With Coastal Eye Associates of Texas Affiliation
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with Coastal Eye Associates (“CEA”). The affiliation represents EyeSouth’s first in the state of Texas and sixteenth a…
Plano Sunglasses Market 2020-2024 | Product Innovation to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalPlanoSunglassesMarket–The Global Plano Sunglasses Market will grow by USD 4.52 bn during 2020-2024
Ocular Therapeutix™ to Present at the Jefferies Virtual Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Impact of the Coronavirus on the Worldwide Ophthalmology Drugs Industry to 2030 – Identify Growth Segments for Investment – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. This report provides the strategists, marketers and senior m…
Global Dry Eye Medication Market Opportunities and Strategies (2019 to 2030) – COVID-19 Impact and Recovery – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. This report provides the strategists, marketers and senior ma…
Simulations Plus Receives New Grant Award from the FDA
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus today announced that it has received a new Grant Award from the FDA to enhance the ocular (OCAT) model in its GastroPlus software.
Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
Insights on the Worldwide Myopia and Presbyopia Treatment Market (2019 to 2028) – Featuring Topcon, Alcon & Nidek Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Myopia and Presbyopia Treatment Market Outlook 2028” report has been added to ResearchAndMarkets.com’s offering. The market for myopia and presbyopia treatment is anticipated to grow at a CAGR of 7.45% during the fo…